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Abstract
High mobility group box-1 (HMGB1) is associated with the pathogenesis of inflammatory diseases. A previous study
reported that intravenous injection of anti-HMGB1 monoclonal antibody significantly attenuated brain edema in a rat model
of stroke, possibly by attenuating glial activation. Peripheral nerve injury leads to increased activity of glia in the spinal cord
dorsal horn. Thus, it is possible that the anti-HMGB1 antibody could also be efficacious in attenuating peripheral nerve
injury-induced pain. Following partial sciatic nerve ligation (PSNL), rats were treated with either anti-HMGB1 or control IgG.
Intravenous treatment with anti-HMGB1 monoclonal antibody (2 mg/kg) significantly ameliorated PSNL-induced hind paw
tactile hypersensitivity at 7, 14 and 21 days, but not 3 days, after ligation, whereas control IgG had no effect on tactile
hypersensitivity. The expression of HMGB1 protein in the spinal dorsal horn was significantly increased 7, 14 and 21 days
after PSNL; the efficacy of the anti-HMGB1 antibody is likely related to the presence of HMGB1 protein. Also, the injury-
induced translocation of HMGB1 from the nucleus to the cytosol occurred mainly in dorsal horn neurons and not in
astrocytes and microglia, indicating a neuronal source of HMGB1. Markers of astrocyte (glial fibrillary acidic protein (GFAP)),
microglia (ionized calcium binding adaptor molecule 1 (Iba1)) and spinal neuron (cFos) activity were greatly increased in the
ipsilateral dorsal horn side compared to the sham-operated side 21 days after PSNL. Anti-HMGB1 monoclonal antibody
treatment significantly decreased the injury-induced expression of cFos and Iba1, but not GFAP. The results demonstrate
that nerve injury evokes the synthesis and release of HMGB1 from spinal neurons, facilitating the activity of both microglia
and neurons, which in turn leads to symptoms of neuropathic pain. Thus, the targeting of HMGB1 could be a useful
therapeutic strategy in the treatment of chronic pain.
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Introduction
High mobility group box-1 (HMGB1) is considered to be a
ubiquitous and abundant nonhistone DNA-binding protein, found
in the nuclei of various cell types including neurons and glial cells
[1]. While HMGB1 is a nuclear protein, interestingly, HMGB1
demonstrates cytokine-like effects in the extracellular space. A
proinflammatory function of HMGB1 has been shown in several
inflammatory disease states, including sepsis, acute lung injury,
rheumatoid arthritis, amyotrophic lateral sclerosis and brain
ischemia [2–8]. Previous studies reported that various inflamma-
tory diseases, including brain infarction induced by the middle
cerebral artery occlusion, brain edema induced by the traumatic
brain injury and diet-induced atherosclerosis, were significantly
ameliorated by treatment with an anti-HMGB1 monoclonal
antibody that neutralizes HMGB1 peptides [7,9–11]. Therefore,
an anti-HMGB1 monoclonal antibody could be a potent
therapeutic for inflammatory diseases [12]. Moreover, recent
studies reported that HMGB1 in rodent spinal cord dorsal horn
and dorsal root ganglion (DRG) plays a critical role in several
animal models of chronic pain including diabetic, cancer and
neuropathic pain [13–16]. To confirm a pro-nociceptive role of
HMGB1, application of HMGB1 to the rat sciatic nerve evoked
an enhanced sensitivity of the hind paw to both noxious and
innocuous stimulation (hyperalgesia and allodynia, respectively)
[15]. These data suggest that peripherally expressed HMGB1 can
significantly modulate nociceptive processing.
There is accumulating evidence that spinal glial cells play a
critical role in the formation of neuronal networks in the central
nervous system [17–19]. Recent studies have clearly shown that
spinal dorsal horn microglia and astrocyte are activated in the
neuropathic pain state [20,21]. Several neuropathic pain models
have shown increased expression of microglia and astrocyte
markers, including ionized calcium binding adaptor molecule 1
(Iba1) and glial fibrillary acidic protein (GFAP), respectively, in the
dorsal horn [22,23]. Activation of glial cells leads to the production
and releases of a variety of inflammatory mediators, including
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cytokines, eicosanoids, neurotrophins and nitric oxide, which in
turn induce nociceptive responses [18,24–28]. While both
microglia and astrocyte are activated following injury or in
response to disease, it is possible that these cells have distinct roles
in the pathology of neuropathic pain [17].
An animal model developed to study neuropathic pain is the
partial sciatic nerve ligation (PSNL) model, which mimics some of
the major features observed in clinical neuropathic pain [29].
Studies have reported an increased permeability of the blood
spinal cord barrier (BSCB) to tracers such as Evans blue and
sodium fluorescein, which was restricted to the lumbar spinal cord,
which began 3 days after PSNL and lasted for at least 4 weeks
following PSNL. Also, injury to a peripheral nerve and electrical
stimulation of C-fibers each caused an increase in the permeability
of the BSCB [30,31]. Thus, in the PSNL model, large molecules,
including antibodies, and immune cells can penetrate into or leak
from the spinal cord, which suggests that a breakdown of BSCB is
critical in the development of neuropathic pain. At the same time,
the permeability of the BSCB following nerve injury could serve as
a doorway into the spinal cord for large molecule-therapeutics.
It has been reported that a single injection with neutralizing
anti-HMGB1 antibody into spinal cord attenuated diabetes-
induced hypersensitivity in mice [14]. Thus, HMGB1 in spinal
cord plays an important role in modulating pain sensation. In
addition, a recent study showed that peripheral treatment with
antibody attenuated subsequent mechanical allodynia in a rodent
neuropathic pain model [15]. In that study, antibody was applied
continuously to the injured nerve root for 7 days via an osmotic
minipump. However, the effect of a systemic, acute treatment with
anti-HMGB1 monoclonal antibody on neuropathic pain and the
mechanism underlying the pro-nociceptive effect of HMGB1 in
the spinal dorsal horn has yet to be determined. Systemic
treatment with a neutralizing antibody could neutralize not only
HMGB1 expressed in injured peripheral nerves and circulating
HMGB1 but also that found in the spinal parenchyma. Hence,
systemic treatment could also be beneficial for treating neuro-
pathic pain.
The current study investigated the behavioral effect of
intravenous (i.v.) injection of an anti-HMGB1 monoclonal
antibody in rats with a PSNL. In addition, the current study
elaborated the expression of HMGB1 in the spinal dorsal horn
following PSNL and, furthermore, elucidated the mechanism of
the antinociceptive effect of the antibody, by observing the activity
of dorsal horn neurons and glial cells following antibody
treatment.
Materials and Methods
Animals and animal care
Male Wistar rats, 5 to 8 weeks of age, were purchased from
SHIMIZU Laboratory Supplies Co., Ltd. Rats were housed at a
room temperature of 2262uC with a 12 h light/dark cycle (lights
on from 8:00 A.M. to 8:00 P.M.) and given access to food and
water available ad libitum during the experimental period. Animal
experiments were conducted in accordance with the ‘‘Guidelines
for the Care and Use of Laboratory Animals’’ established by
Hiroshima University, and all experimental procedures involving
animals were approved by the Committee of Research Facilities
for Laboratory Animal Science of Hiroshima University (Permit
Number: A10-2-2).
Partial sciatic nerve ligation model
The rats were anesthetized with sodium pentobarbital (50 mg/
kg, i.p.). To induce a unilateral mononeuropathy, a tight ligation
of approximately one-third to one-half of the diameter of the left
sciatic nerve (ipsilateral) was performed with 6-0 silk suture as
described previously [29]. In sham-operated rats, the nerve was
exposed without ligation.
Hind paw sensitivity to tactile stimulation
Three, 7, 14 and 21 days post-surgery, the plantar surface of the
hind paws was probed with von Frey monofilaments (Natsume
Seisakusho Co., Tokyo, Japan), starting with the filament that
exerts 0.16 g of force. When the animal responded to the filament
(which included lifting and licking of the hind paw), a lower force
von Frey filament was used. If the animal did not respond, a
higher force von Frey filament was applied. Each hind paw was
tested three times. Either an anti-HMGB1 monoclonal antibody
(IgG2a subclass, 2 mg/kg) or class-matched control monoclonal
antibody (anti-Keyhole Limpet hemocyanin) was administered intrave-
nously immediately following baseline withdrawal threshold
determination.
Western blot
Under ether anesthesia, rats were decapitated, the lumbar (L4–
L6) segments of the spinal dorsal horn were removed and
immediately frozen in liquid nitrogen and stored at –80uC until
use. Spinal tissues were solubilized in radioimmunoprecipitation
assay (RIPA) buffer with protease inhibitors (100 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 20 mg/
ml aprotinin, 20 mg/ml leupeptin, and 1 mM phenylmethylsulfo-
nyl fluoride). The tissue lysates were then added to Laemli’s buffer
and boiled for 5 min. Equal amounts of protein were separated by
12.5% SDS–polyacrylamide gel electrophoresis and blotted onto
nitrocellulose membranes. The membranes were blocked in
blocking buffer (20% skim milk in Tris buffered saline with
Tween 20) for 2 h at room temperature, and subsequently
incubated with a purified horseradish peroxidase (HRP)-conju-
gated monoclonal antibody against HMGB1 (1:500), a monoclo-
nal antibody against GFAP (1:2,000), a polyclonal antibody
against Iba1 (1:1,000), a polyclonal antibody against cFos (1:1,000)
or a monoclonal antibody against b-actin (1:20,000) overnight at
4uC. After washing, the membranes were incubated with a HRP-
linked anti-mouse IgG antibody (1:2,500) or a HRP-linked anti-
rabbit secondary antibody (1:2,500) for 1 h at room temperature.
The membranes were then rinsed and incubated with Lumines-
cence reagent (Thermo Fisher Scientific, Rockford, IL, USA).
Finally, the membranes were exposed to X-ray film to detect
the protein. For quantification of signals, the densities of specific
bands were measured with Science Lab Image Gauge (Fuji Film,
Tokyo, Japan). Specific bands for GFAP, Iba1, HMGB1, cFos and
b -actin were detected at 51, 17, 30, 62 and 42 kDa, respectively.
Immunohistochemistry
Under sodium pentobarbital anesthesia (50 mg/kg, i.p), rats
were transcardially perfused with 50 ml of saline followed by
150 ml of freshly prepared 4% (w/v) paraformaldehyde in 0.1 M
phosphate buffer (pH=7.4). The spinal cord tissue was quickly
removed and postfixed in the same fixative solution for three days
at 4uC and then cryoprotected overnight in 30% (w/v) sucrose in
0.1 M phosphate buffer at 4uC. The tissue was embedded in
Tissue-Tek OCT compound 4583 (Sakura Finetech, Tokyo,
Japan) and frozen in liquid nitrogen, cut serially (30 mm thickness)
in a cryostat, and collected onto glass slides (MAS-GP type A;
Matsunami Glass, Osaka, Japan). After slides were dried at room
temperature, tissue sections were processed for immunohisto-
chemistry for cFos or double-labeling immunohistochemistry for
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HMGB1 and NeuN, HMGB1 and GFAP, HMGB1 and Iba1.
The tissue sections were rinsed with phosphate-buffered saline,
incubated in a blocking solution of 10% goat serum, 3% bovine
serum albumin, 0.1% Triton X and 0.05% Tween-20 in
phosphate-buffered saline for 2 h at room temperature, and then
incubated with a mixture of mouse anti-GFAP antibody (1:1,000),
mouse anti-HMGB1 antibody (1:250), rabbit anti-Iba1 antibody
(1:1,000), rabbit anti-NeuN antibody (1:1,000), rabbit anti-GFAP
antibody (1:1,000) and rabbit anti-cFos antibody (1:1,000) for 72 h
at 4uC, followed by 4’,6-diamidino-2-phenylindole (DAPI, 0.5 mg/
mL) and corresponding secondary antibodies conjugated with
Alexa FluorH 488 (1:200) and 555 (1:250) for 2 h at 4uC in a dark
chamber. The sections were then extensively washed in phos-
phate-buffered saline and then coverslipped. Sections were
examined with a BZ-9000 Biorevo all-in-one fluorescence
microscope (Keyence, Elmwood Park, NJ, USA). For quantifica-
tion of signals, both immunoreactive intensity and area were
measured with Image J software (NIH, Bethesda, USA).
Because of the technical difficulty in dividing tissue samples
taken from experimental animals into cytosolic and nuclear
fractions and at the same time determining the cell type in which
translocation occurs HMGB1, we have devised a simple method of
quantifying HMGB1 translocation as observed by immunocyto-
chemistry. Cytoplasmic translocation of HMGB1 should result in
an area of immunofluorescence that is greater than the area of
DAPI, or non-translocated, nuclear HMGB1, immunofluores-
cence. Thus, as a measure of in vivo HMGB1 translocation, the
ratio of the area of HMGB1 immunofluorescence to the area of
DAPI immunofluorescence (as assessed using Image J) was
calculated and this method was applied to glia as well as neurons.
A value of 100 indicates nuclear HMGB1 (or a lack of cytoplasmic
translocation) whereas values greater than 100 indicate cytoplas-
mic translocation of HMGB1.
Materials
Anti-mouse IgG HRP-linked antibody (Cat. #7074S, Lot.
#H0111) and anti-rabbit IgG HRP-linked antibody (Cat.
#7074S, Lot. #C2812; Cell Signaling Technology, Beverly,
MA, USA); Pentobarbital (Dainippon Sumitomo Pharma, Osaka,
Japan); anti-rabbit GFAP antibody (Cat. #GTX72747, Lot.
#14496; Gene Tex, Irvine, CA, USA); goat anti-rabbit IgG
antibody (Alexa Fluor 555, Cat. #A-21428, Lot. #853493) and
goat anti-mouse IgG antibody (Alexa Fluor 488, Cat. #A-11001,
Lot. #877595; Invitrogen, Burlington, ON, Canada); anti-mouse
GFAP antibody (Cat. #MAB360, Lot. #LV1718394) and anti-
rabbit NeuN antibody (Cat. #MAB377, Lot. #1949597; Milli-
pore Corporation, Bedford, MA, USA); bovine serum albumin
(Nissui, Tokyo, Japan); DAPI (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); anti-mouse b-actin antibody (Cat. #A5441, Lot.
#055K4854; Sigma-Aldrich Co., St. Louis, MO, USA) and anti-
rabbit Iba1 antibody (Cat. #019-19741, Lot. #WEK6254; Wako
Pure Chemical Industries, Osaka, Japan). All other reagents were
of the highest purity available from commercial sources. The anti-
HMGB1 rat monoclonal antibody was produced as described
previously [7,9].
Statistical analysis
Values are expressed as mean 6 SEM. Comparisons of
expression of the spinal dorsal horn HMGB1 protein was
performed using Student’s t-test. The data from the PSNL
induced-mechanical hypersensitivity were analyzed using two-
way analysis of variance (ANOVA) followed by the Tukey-Kramer
test for post hoc comparisons, while data from the other experiments
(comparisons between treatments) were analyzed using a one-way
ANOVA followed by the Tukey-Kramer test for post hoc
comparisons. A probability value (p) of less than 0.05 was
considered to be statistically significant.
Results
PSNL evoked mechanical hypersensitivity and activation
of spinal glial cells
The development of long-lasting mechanical hypersensitivity in
the left hind paw of PSNL rats was observed for 21 days after
surgery (F1, 40 = 5.61, p,0.01, two-way ANOVA for repeated
measures; Fig. 1). Rats with a PSNL had significantly lower
withdrawal thresholds, compared with pre- surgery thresholds, of
the ipsilateral paw at every time point after surgery (PSNL, pre:
6.0060.00 g, 3 days: 0.3960.07 g, 7 days: 0.3560.05 g, 14 days:
0.3060.06 g, 21 days: 0.3560.05 g). By contrast, sham-operated
rats did not display significant mechanical hypersensitivity (Sham,
pre: 4.4060.75 g, 3 days: 5.4061.47 g, 7 days: 5.2061.36 g, 14
days: 5.2061.20 g, 21 days: 4.4060.75 g,).
The rats displayed good overall health after either PSNL or
sham surgery, with standard locomotor activity throughout the
experimental period of evaluation.
Effect of systemic treatment with anti-HMGB1
monoclonal antibody on PSNL-evoked mechanical
hypersensitivity
As shown in Figure 2, systemic administration with an anti-
HMGB1 monoclonal antibody (anti-HMGB1, 2 mg/kg, i.v.)
significantly attenuated mechanical hypersensitivity induced by
PSNL on days 7, 14, and 21, but not 3 days, post-surgery. The
antinociceptive effect lasted for at least 3 hr after i.v. administra-
tion. By contrast, treatment with a control IgG antibody (2 mg/kg,
i.v.) had no effect on withdrawal thresholds.
Figure 1. Partial Sciatic Nerve Ligation (PSNL) produces hind
paw mechanical hypersensitivity in rats. Withdrawal thresholds of
the ipsilateral hind paw following PSNL were assessed over time with
von Frey filaments in sham and PSNL rats for the periods indicated. Data
are expressed as mean 6 SEM. n = 5/group. ** p,0.01 compared with
pre-surgery (one-way ANOVA followed by Tukey-Kramer post hoc test).
{{ p,0.01 compared with sham group (Student’s t-test).
doi:10.1371/journal.pone.0073640.g001
Anti-HMGB1 Antibody Alleviates Neuropathic Pain
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e73640
HMGB1 up-regulation induced by PSNL surgery in spinal
dorsal horn
The expression levels of HMGB1 were determined on days 3, 7,
14 and 21 after PSNL by Western blotting. As shown in Figure 3A,
levels of HMGB1 in ipsilateral dorsal horn were significantly
elevated 7, 14 and 21 days, but not 3 days, after PSNL compared
with levels of HMGB1 in dorsal horn from sham-operated rats. By
contrast, PSNL surgery did not significantly affect expression levels
of HMGB1 mRNA in DRG (Fig. S1).
In the spinal dorsal horn, HMGB1 immunofluorescence
intensity was enhanced at 21 days, but not 3 days, post-PSNL
compared with dorsal horn from sham-operated rats (Fig. 3 B-E).
Moreover, double-labeled immunostaining for HMGB1 and
NeuN revealed that translocation of HMGB1 from the nucleus
to the cytosol occurred in dorsal horn neurons on day 21 post-
PSNL (Fig. 4A and B). In contrast, HMGB1 immunoreactivity in
both astrocytes and microglia remained in the nucleus 21 days
after PSNL (Figure 4C-F). In addition, immunoreactive intensity
of the PSNL-induced increase in HMGB1 could be demonstrated
only in the neurons (Figure 4G). Using this simple calculation, we
have found a significant cytoplasmic translocation of HMGB1
(ratio greater than 100) in neurons but not in astrocytes and
microglia (ratio about 100; Figure 4H).
Effect of anti-HMGB1 monoclonal antibody on PSNL-
evoked activation of glial cells and neurons
The morphological changes in spinal microglia and astrocytes in
the dorsal horn 21 days after PSNL, which could be considered the
late maintenance phase of neuropathic pain in this model, were
investigated by using immunohistochemistry. Twenty one days
following PSNL, GFAP and Iba1-positive cells were increased in
the ipsilateral spinal dorsal horn, whereas they were not increased
in sham-operated rats (Fig. 5A and B). Intravenous injection with
anti-HMGB1 monoclonal antibody (2 mg/kg) dramatically
changed the morphologies of microglia, but not astrocytes, from
ameboid state to ramified state (Fig. 5C and D). To quantify these
levels of activation, protein levels of glial markers were examined
by western blotting analysis after the treatment with anti-HMGB1
monoclonal antibody. The protein level of Iba1, but not GFAP,
was significantly down-regulated 2 hr after treatment with anti-
HMGB antibody (Fig. 5E and F). By contrast, injection with the
control antibody had no effect on either Iba1 or GFAP expression
in rats with a PSNL.
Next, to examine the degree of neural activity in the ipsilateral
spinal dorsal horn, the protein level of cFos, an immediate early
gene product and a marker of neuronal activation, was measured.
A marked increase of cFos protein was obtained 21 days after
PSNL. By contrast, no significant increase in cFos was observed
following sham surgery. Furthermore, the increase of cFos in rats
with a PSNL was significantly attenuated by treatment with an
anti-HMGB1 monoclonal antibody (Fig. 6). No effect of the
control antibody on cFos expression was observed in PSNL rats.
Discussion
The current study demonstrated that a single systemic (i.v.) dose
of anti-HMGB1 monoclonal antibody ameliorated PSNL-induced
mechanical hypersensitivity for several hours during the mainte-
nance phase (7, 14, 21 days), but not the induction phase (3 days),
of neuropathic pain. The efficacy is likely due to neutralizing the
effect of HMGB1 released from cells within the spinal dorsal horn.
Figure 2. Antinociceptive effect of anti-HMGB1 monoclonal antibody on PSNL-induced mechanical hypersensitivity in rats. Effects of
intravenous injection of either anti-HMGB1 monoclonal antibody (anti-HMGB1, 2 mg/kg) or control IgG (2 mg/kg) on nociceptive behaviors over time
in rats with either sham or PSNL surgery (A, E: 3 days, B, F: 7 days, C, G: 14 days, D, H: 21 days). A single dose of anti-HMGB1 monoclonal antibody
increased withdrawal thresholds in rats with a PSNL, but not sham, surgery. Data are expressed as mean 6 SEM. n = 5/group. * p,0.05, ** p,0.01
compared with sham group (Student’s t-test). { p,0.05 compared with pre-operation (one-way ANOVA followed by Tukey-Kramer post hoc test).
doi:10.1371/journal.pone.0073640.g002
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The current study demonstrated an increase of neuronal HMGB1
in the ipsilateral dorsal horn, which was translocated from the
nucleus to the cytoplasm, indicating a potential source of
extracellular HMGB1. Although HMGB1 was also expressed in
glial cells, translocation of HMGB1 to the cytoplasm was not
observed in glial cells, further suggesting that the source of secreted
HMGB1 in spinal dorsal horn was from neurons. These results
indicate that an increase of HMGB1 secretion from the spinal
dorsal neurons is associated with the maintenance of the
neuropathic pain state, and that a treatment against anti-HMGB1
that neutralizes HMGB1 could be a useful therapeutic strategy for
ameliorating neuropathic pain.
It has been well established that HMGB1 is not only passively
secreted during cellular necrosis by nearly all cell types that have a
nucleus and serves to signal neighboring cells of ongoing damage
but also actively secreted from neurons and immune cells such as
macrophages and microglia following stimulation with lipopoly-
saccharide (LPS) or tumor necrosis factor (TNF)-a [3,32].
Secretion of HMGB1 can trigger the release of numerous
cytokines from inflammatory cells and lead to a positive-feedback
autocrine loop, thereby leading to the further release of HMGB1
and maintenance of the inflammatory cascade [33,34]. Previous
studies have reported that pain-related behaviors in several
preclinical models of chronic pain, including diabetic, cancer
and neuropathic pain, were significantly attenuated by treatment
with anti-HMGB1 antibody [14–16]. These studies suggest that
the HMGB1 may be involved in the maintenance of chronic pain.
In the current study, a significant increase of HMGB1 in the
spinal dorsal horn occurred 7 days following nerve injury and
continued for an additional two weeks, even though significant
hind paw mechanical hypersensitivity was observed beginning 3
days after nerve ligation. Moreover, the current findings indicate
that HMGB1 originates from spinal dorsal horn neurons, and not
glial cells, suggested by the translocation of HMGB1 to the
cytoplasm from the nucleus in neurons. These data coincide with a
previous study that demonstrated that HMGB1 was translocated
and released from neurons, not glial cells, in the ischemic rat brain
[9]. Thus, these data suggest that the HMGB1 secreted from
dorsal horn neurons may play an important role in regulating
‘‘late’’ or maintenance phase of neuropathic pain. However, the
neurochemical mechanism that mediates HMGB1 upregulation
and secretion form spinal dorsal horn neurons in the late phase of
neuropathic pain is unclear. One possible mechanism could be
thought cytokines released from activated microglia and/or
primary afferent neuron in the ‘‘early’’ or induction phase of
neuropathic pain. Several studies have demonstrated that TNF-a
Figure 3. Expression level of HMGB1 was increased in rat lumbar spinal cord dorsal horn after PSNL. A. The expression of HMGB1 in the
ipsilateral spinal dorsal horn of sham (post-Sham 3–21 days) and PSNL (post-PSNL 3–21 days) rats at the indicated periods were measured by Western
blotting. The optic densities of HMGB1 were normalized to that of sham rats at the corresponding time point. n = 4/group. B, C. Immunolabeling of
HMGB1 within spinal dorsal horn of sham and PSNL rats at 3 (B) and 21 days (C) following operation. Scale bar = 200 mm. D, E. Quantitative analysis
of HMGB1 expression at 3 (D) and 21 days (E) following operation. Data indicate the relative mean immunofluorescence intensity of spinal dorsal
horn. Data are expressed as mean 6 SEM. n= 3/group. *, ** p,0.05, 0.01 compared with sham group (Student’s t-test).
doi:10.1371/journal.pone.0073640.g003
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is secreted from cultured microglia and DRG neurons, and that
TNF-a stimulation modulates the expression and secretion of
HMGB1 [27,32,35]. Furthermore, Wang et al. reported that the
intrathecal injection of Etanercept, a recombinant TNF receptor
(p75)-Fc fusion protein, inhibited the increased expression of
HMGB1 by chronic constriction injury of the sciatic nerve [36]. In
addition, HMGB1 release occurs considerably later than the
secretion of typical pro-inflammatory mediators TNF-a and
interleukin (IL)-1 [3,34]. Thus, a possible sequence of events that
leads to the maintenance of nerve injury-induced pain is that
peripheral nerve injury evokes cytokine release from activated
spinal microglia and/or primary afferent neurons, thereby leading
to the upregulation and secretion of HMGB1 from spinal dorsal
horn neurons.
The current study also showed that the nerve injury-induced
mechanical allodynia, 21 days post-ligation, is significantly
attenuated by i.v. anti-HMGB1 monoclonal antibody with a
concurrent reduction of markers of neuronal and microglia
activity. It is particularly interesting that acute i.v. administration
of antibody effectively reduced mechanical allodynia. Intravenous
injection would be a convenient means of delivery since currently
available antibody drugs are injectables. Also, it is possible that the
anti-HMGB1 monoclonal antibody reached the target tissue, the
spinal cord, because of the significantly increased permeability of
the BSCB following PSNL, thereby blocking HMGB1 function in
both the spinal cord and in the circulation [30].
Pain hypersensitivity is thought to be due in part to altered
processing of signals in the spinal nociceptive system
[17,18,20,21]. The current study confirms altered spinal neuronal
activity following PSNL, by increased cFos immunoreactivity and
this increase, along with cutaneous hypersensitivity, was dimin-
ished by anti-HMGB1 treatment. The present study also
Figure 4. Distribution of HMGB1 expression in spinal dorsal horn neurons and glial cells. A-F. Double-labeling immunohistochemistry for
HMGB-1 and NeuN (A, B, a marker for neurons), GFAP (C, D, a marker for astrocytes) or Iba1 (E, F, a marker for microglia) in the spinal dorsal horn of
sham (A, C, E) and PSNL (B, D, F) rats 21 days following operation. DAPI was used to show nuclear localization. Scale bar = 10 mm. G. Quantitative
analysis of HMGB1 expression level in neurons, astrocytes and microglia at 21 days following operation. Data indicate the relative mean
immunofluorescence intensity of a single cell. H. Quantitative analysis of the area of HMGB1 expression of neurons, astrocytes and microglia at 21
days following operation. Mean ratios of the area of HMGB1 immunofluorescence to the area of DAPI immunofluorescence are shown. Data are
expressed as mean 6 SEM. n = 6/group. * p,0.05 compared with sham group (Student’s t-test).
doi:10.1371/journal.pone.0073640.g004
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confirmed increased expression following a nerve injury of
activation markers in microglia and astrocytes in spinal dorsal
horn, but only Iba1 was suppressed by anti-HMGB1 treatment.
Previous studies have reported that HMGB1-induced inflamma-
tion via the activation of inflammatory cells including macro-
phages and microglia [7,8,37,38]. Moreover, Leclerc et al.
reported that co-treatment with HMGB1/IL1b significantly
increased the expression of microsomal prostaglandin E syn-
thase-1 and cyclooxygenase-2 as well as prostaglandin E2
production compared to treatment with either HMGB1 or IL-
1b alone [39]. Indeed, that anti-HMGB treatment did not
completely reverse PNSL-induced hypersensitivity suggests that
other substances released from spinal tissue following nerve injury
may be crucial in the maintenance of the neuropathic pain state.
Nonetheless, the data suggest that HMGB1, in concert with other
substances, potentiates nociceptive processing following nerve
injury at the level of the spinal cord via activation of microglia.
While the Iba1 and cFos were attenuated, the astrocytic marker
GFAP was not attenuated, despite the fact that astrocytes are
important for the maintenance of neuropathic pain [17,18,21].
Ren et al. reported that diabetes-induced astrocytic activation
in the spinal dorsal horn is attenuated by intrathecal injection of
anti-HMGB1 antibody [14]. Recently, studies have shown that
astrocytes are activated by numerous substances, including
cytokines/chemokines (e.g., TNF-a, IL-1b, IL-6 and IL-18),
and neurotransmitters (e.g., glutamate, substance P, calcitonin
Figure 5. Effect of anti-HMGB1 monoclonal antibody on activation of spinal dorsal horn glial cells after PSNL. A, B.
Immunofluorescence photomicrographs of spinal dorsal horn astrocytes (A) and microglia (B) from rats treated 2 hrs after with either anti-
HMGB1 monoclonal antibody (2 mg/kg) or control IgG (2 mg/kg). Sham and PSNL rats were treated with antibody 21 days after operation. Scale bar
= 200 mm. C, D. High-power fields demonstrating morphological change of astrocytes (C) and microglia (D). Scale bar = 20 mm. E, F. Levels of GFAP
(E) and Iba1 (F) in the ipsilateral dorsal horn were quantified by Western blotting analysis. The panels indicate representative blots. The graph in lower
panels indicates quantitative data for each blot. Protein levels were normalized to levels of b-actin. Data are expressed as mean6 SEM. n = 5/group. *,
** p,0.05, 0.01 compared with sham-control IgG group, { p,0.05 compared with PSNL-control IgG group (one-way ANOVA followed by Tukey-
Kramer post hoc test).
doi:10.1371/journal.pone.0073640.g005
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gene-related peptide and ATP), in addition to HMGB1 [21].
Therefore, mediators in addition to HMGB1 could be crucial role
in initiating and maintaining astrocyte activitation following nerve
injury.
In conclusion, the current results indicate that nerve injury
evokes HMGB1 release from dorsal horn neurons, and subsequent
activation of spinal neuron and microglia by HMGB1 maintains
the neuropathic pain state. Thus, blocking HMGB1 function, such
as through an antibody, could prove to be a potent therapeutic
strategy for the treatment of neuropathic pain.
Supporting Information
Figure S1 Expression level of HMGB1 mRNA in rat
DRG after PSNL. Expression levels of HMGB1 mRNA in the
ipsilateral or contralateral DRG of sham (post-Sham 7-21 days)
and PSNL (post-PSNL 7-21 days) rats at the indicated periods
were measured by real-time PCR. Data are expressed as a ratio to
sham values. Data are mean 6 SEM. n= 4/treatment group.
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